Press Releases

Unedited news and product information from vendors.

Pharsight Achieves 20th PKS(TM) Customer Milestone
Oct 01, 2007 (06:10 AM EDT)

MOUNTAIN VIEW, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that it has added another global pharmaceutical company to its Pharsight(R) Knowledgebase Server(TM) (PKS(TM)) customer roster. The company, ranked in Pharmaceutical Executive's 2007 Top 50 list as measured by prescription drug sales, has signed an agreement for PKS user licenses and associated deployment services. This new agreement brings Pharsight's total number of PKS customers to 20.

Pharsight's newest PKS customer currently holds more than 20 licenses for WinNonlin(R), Pharsight's industry standard pharmacokinetic/pharmacodynamic (PK/PD) modeling and analysis software. The customer will use PKS, which is directly integrated with WinNonlin, as a central repository for PK/PD data and will access PKS from research and development sites in the US, Europe and Asia.

"Signing our twentieth PKS customer marks an important milestone in our strategy to bring the benefits of automated PK/PD data management to the pharmaceutical and biotechnology industries," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "This purchase also underscores our assertion that companies with five or more licenses of WinNonlin are prime candidates to adopt PKS. We believe that these customers have a level of analysis and modeling activity where a secure and scalable data repository like PKS can provide a unique return on investment in terms of cost and human capital. We currently have approximately 100 customers that have five or more seats of WinNonlin and we are excited about the opportunities to continue to expand our PKS user base."

About PKS

PKS is a high-productivity, regulatory-compliant enterprise data repository that manages modeling and simulation data. PKS enables pharmaceutical and biotechnology companies to better manage and control preclinical and clinical PK/PD data and analyses, thus supporting higher modeling productivity as called for in the FDA's Critical Path Initiative.

Companies also use PKS to build PK/PD data management architecture that complies with the FDA's regulation 21 CFR Part 11, which has set new standards for computer system validation and usage. PKS is directly integrated with WinNonlin Enterprise, Pharsight's industry-leading PK/PD modeling and analysis tool, for state-of-the-art modeling and analyses, and supports direct access to any ODBC-capable data source. PKS also supports analysis with leading tools such as NONMEM(R), and SAS(R), and data import from leading clinical data management and laboratory information management systems such as Watson LIMS(TM). PKS software is designed to complement other Pharsight products, including Trial Simulator(TM) and Drug Model Explorer(R) (DMX(R)), which are used for computer-based drug-disease modeling, clinical trial simulation, and drug model visualization.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at .

Forward Looking Statements

The statements in this press release related to the performance, benefit and potential market size of the Pharsight Knowledgebase Server (PKS) are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: changes in FDA regulations and customers may not perceive the benefits and market size of PKS to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on August 13, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.

Registered Trademarks and Trademarks

Pharsight, Pharsight Knowledgebase Server, PKS, Drug Model Explorer, DMX, Trial Simulator and WinNonlin are trademarks or registered trademarks of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.

CONTACT: Investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-646-201-5447, or Media, Jen Saunders, +1-646-201-5431, allof EVC Group for Pharsight Corporation

Web site: